


IFW #

D0273 NP

**CERTIFICATE OF MAILING**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Stephen C. D'Amico  
Type or print name

  
Signature

10-5-06  
Date

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF

ART UNIT: 1656

FEI HUANG, ET AL.

EXAMINER: SWOPE, SHERIDAN

APPLICATION NO: 10/648,593

FILED: 08/26/2003

FOR: IDENTIFICATION OF POLYNUCLEOTIDES FOR PREDICTING  
ACTIVITY OF COMPOUNDS THAT INTERACT WITH AND/OR  
MODULATE PROTEIN TYROSINE KINASES AND/OR PROTEIN  
TYROSINE KINASE PATHWAYS IN BREAST CELLS

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT**


Sir:


Please charge Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

Respectfully submitted,

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000

  
Stephen C. D'Amico  
Agent for Applicant  
Reg. No. 46,652  
Phone: 609-252-5289  
Date: 10-5-06




CASE D0273 NP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Stephen C. D'Amico  
Type or print name

  
Signature

10-5-06  
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1656

HUANG ET AL.

Examiner: SWOPE, SHERIDAN

APPLICATION NO: 10/648,593

FILED: AUGUST 26, 2003

FOR: IDENTIFICATION OF POLYNUCLEOTIDES FOR PREDICTING  
ACTIVITY OF COMPOUNDS THAT INTERACT WITH AND/OR  
MODULATE PROTEIN TYROSINE KINASES AND/OR PROTEIN  
TYROSINE KINASE PATHWAYS IN BREAST CELLS

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c).  
A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the  
references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.


10/12/2006 WASFAW1 00000096 193880 10648593

01 FC:1806 180.00 DA

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(609) 252-5289

  
\_\_\_\_\_  
Stephen C. D'Amico  
Agent for Applicants  
Reg. No. 46,652

Date: 10-5-06

Substitute for form 1449/PTO

**COMPLETE IF KNOWN**

Application Number	10/648593
Filing Date	08/26/2003
First Named Inventor	FEI HUANG
Art Unit	1656
Examiner Name	SWOPE, SHERIDAN
Attorney Docket Number	D0273 NP

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT(S)**

(use as many sheets as necessary)

Sheet 1 of 3**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article(when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Check box if English language Translation is attached
	AA	Baselga, et al., "Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185 <sup>HER2</sup> Monoclonal Antibody in Patients with HER2/ <i>neu</i> -Overexpressing Metastatic Breast Cancer", J. Clin. Oncol., Vol. 14(3), pp. 737-744 (1996)	
	AB	Bild, et al., "Oncogenic Pathway Signatures in Human Cancers as a Guide to Targeted Therapies", Nature, Vol. 439, pp. 353-357 (2006)	
	AC	Brenton, et. al., "Molecular Classification and Molecular Forecasting of Breast Cancer: Ready for Clinical Application?", J. Clin. Oncol., Vol. 23(29), pp. 7350-7360 (2005)	
	AD	Burgess, et al., "Comparative Analysis of Two Clinically Active BCR-ABL Kinase Inhibitors Reveals the Role of Conformation-Specific Binding in Resistance", PNAS, Vol. 102, pp. 3395-3400 (2005)	
	AE	Carlini, et al., "UGT1A7 and UGT1A9 Polymorphisms Predict Response and Toxicity in Colorectal Cancer Patients Treated with Capecitabine/Irinotecan", Clin. Can. Res., Vol. 11, pp. 1226-1236 (2005)	
	AF	Dressman, et al., "Gene Expression Profiles of Multiple Breast Cancer Phenotypes and Response to Neoadjuvant Chemotherapy", Clin. Can. Res., Vol. 12(3), pp. 819-826 (2006)	
	AG	Duxbury, et al., "CEACAM6 Cross-linking Induces Caveolin-1-dependent, Src-mediated Focal Adhesion Kinase Phosphorylation in BxPC3 Pancreatic Adenocarcinoma Cells", J. Biol. Chem., Vol. 279(22), pp. 23176-23182 (2004)	
	AH	Biscardi, et al., "c-SRC, Receptor Tyrosine Kinases, and Human Cancer", Adv. Can. Res., Vol. 9(6), pp. 61-119 (1999)	
	AI	Eliceiri, et al., "Selective Requirement for Src Kinases during VEGF-Induced Angiogenesis and Vascular Permeability", Molec. Cell, Vol. 4, pp. 915-924 (1999)	
	AJ	Finn, et al., "Biologic Effects and Identification of Predictive Markers of Response to Dasatinib (BMS-354825), a Novel, Oral, Multi-targeted Kinase Inhibitor in Human Breast Cancer Cell Lines <i>in vitro</i> ", Clin. Can. Res., Vol. 11(24), pp. 9022s (2005)	
	AK	Giancotti, et al., "Integrin Signaling", Science, Vol. 285, pp. 1028-1032 (1999)	
	AL	Horne, et al., "The Role(s) of Src Kinase and Cbl Proteins in the Regulation of Osteoclast Differentiation and Function", Immunol. Rev., Vol. 208, pp. 106-125 (2005)	
	AM	Iwao-Koizumi, et al., "Prediction of Docetaxel Response in Human Breast Cancer by Gene Expression Profiling", J. Clin. Oncol., Vol. 23(3), pp. 422-431 (2005)	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant

PTO/SB/08B (8/03) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE															
Substitute for form 1449/PTO  <div style="text-align: center; font-weight: bold; font-size: 1.2em;">           INFORMATION DISCLOSURE            STATEMENT BY APPLICANT(S)         </div> <div style="text-align: center; font-size: 0.8em;"> <i>(use as many sheets as necessary)</i> </div>		<div style="text-align: center; font-weight: bold; font-size: 0.9em;">           COMPLETE IF KNOWN         </div> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>10/648,593</td> </tr> <tr> <td>Filing Date</td> <td>08/26/2003</td> </tr> <tr> <td>First Named Inventor</td> <td>FEI HUANG</td> </tr> <tr> <td>Art Unit</td> <td>1656</td> </tr> <tr> <td>Examiner Name</td> <td>SWOPE, SHERIDAN</td> </tr> <tr> <td>Attorney Docket Number</td> <td>D0273 NP</td> </tr> </table>		Application Number	10/648,593	Filing Date	08/26/2003	First Named Inventor	FEI HUANG	Art Unit	1656	Examiner Name	SWOPE, SHERIDAN	Attorney Docket Number	D0273 NP
Application Number	10/648,593														
Filing Date	08/26/2003														
First Named Inventor	FEI HUANG														
Art Unit	1656														
Examiner Name	SWOPE, SHERIDAN														
Attorney Docket Number	D0273 NP														
Sheet	2	of	3												

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article(when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Check box if English language Translation is attached
	2AA	Johnson, et al., "Dasatinib (BMS-354825) Tyrosine Kinase Inhibitor Suppresses Invasion and Induces Cell Cycle Arrest and Apoptosis of Head and Neck Squamous Cell Carcinoma and Non-Small Cell Lung Cancer Cells", Clin. Can. Res., Vol. 11(19), pp. 6924-6932 (2005)	
	2AB	Landen, et al., "EphA2 as a Target for Ovarian Cancer Therapy", Expert Opin. Ther. Targets, Vol. 9(6), pp. 1179-1187 (2005)	
	2AC	Lynch, et al., "Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib", New Engl. J. Med., Vol. 350(21), pp. 2129/2139 (2004)	
	2AD	Mao, et al., "Activation of c-Src by Receptor Tyrosine Kinases in Human Colon Cancer Cells with High Metastatic Potential", Oncogene, Vol. 15, pp. 3083-3090 (1997)	
	2AE	Mariadason, et. al., "Gene Expression Profiling-Based Prediction of Response of Colon Carcinoma Cells to 5-Fluorouracil and Camptothecin", Can. Res., Vol. 63, pp. 8791-8812 (2003)	
	2AF	Myoui, et al., "C-Src Tyrosine Kinase Activity Is Associated with Tumor Colonization in Bone and Lung in an Animal Model of Human Breast Cancer Metastasis", Can. Res., Vol. 63, pp. 5028-5033 (2003)	
	2AG	Nam, et al., "Action of the Src Family Kinase Inhibitor, Dasatinib (BMS-354825), on Human Prostate Cancer Cells", Can. Res., Vol. 65(20), pp. 9185-9189 (2005)	
	2AH	Pao, et al., "EGF Receptor Gene Mutations are Common in Lung Cancers from 'Never Smokers' and are Associated with Sensitivity of Tumors to Gefitinib and Erlotinib", PNAS, Vol. 101, pp. 13306-13311 (2004)	
	2AI	Pawitan, et al., "Gene Expression Profiling Spares Early Breast Cancer Patients from Adjuvant Therapy: Derived and Validated in Two Population-Based Cohorts", Breast Can. Res., Vol. 7, pp. R953-R964 (2005)	
	2AJ	Perou, et al., "Molecular Portraits of Human Breast Tumours", Nature, Vol. 406, pp. 747-752 (2000)	
	2AK	Peters, et al., "Genome-wide Transcriptional Analysis of Carboplatin Response in Chemosensitive and Chemoresistant Ovarian Cancer Cells", Mol. Can. Ther., Vol. 4(10), pp. 1605-1616 (2005)	
	2AL	Roberts, et al., "Identification of Genes Associated with Platinum Drug Sensitivity and Resistance in Human Ovarian Cancer Cells", Brit. J. Can., Vol. 92, pp. 1149-1158 (2005)	
	2AM	Rouzier, et al., "Microtubule-associated Protein Tau: A Marker of Paclitaxel Sensitivity in Breast Cancer", PNAS, Vol. 102, pp. 8315-8320 (2005)	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

considered. Include a copy of this form with the next communication to applicant

PTO/SB/08B (8/03) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE															
Substitute for form 1449/PTO  <div style="text-align: center;"> <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT(S)</b>  <small>(use as many sheets as necessary)</small> </div>		<div style="text-align: center; border: 1px solid black; background-color: #f0f0f0; margin-bottom: 5px;"> <b>COMPLETE IF KNOWN</b> </div> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr><td style="width: 50%;">Application Number</td><td>10/648,593</td></tr> <tr><td>Filing Date</td><td>08/26/2003</td></tr> <tr><td>First Named Inventor</td><td>FEI HUANG</td></tr> <tr><td>Art Unit</td><td>1656</td></tr> <tr><td>Examiner Name</td><td>SWOPE, SHERIDAN</td></tr> <tr><td>Attorney Docket Number</td><td>D0273 NP</td></tr> </table>		Application Number	10/648,593	Filing Date	08/26/2003	First Named Inventor	FEI HUANG	Art Unit	1656	Examiner Name	SWOPE, SHERIDAN	Attorney Docket Number	D0273 NP
Application Number	10/648,593														
Filing Date	08/26/2003														
First Named Inventor	FEI HUANG														
Art Unit	1656														
Examiner Name	SWOPE, SHERIDAN														
Attorney Docket Number	D0273 NP														
Sheet	3	of	3												

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article(when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Check box if English language Translation is attached
	3AA	Shah, et al., "Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor", Science, Vol. 305, pp. 399-401 (2004)	
	3AB	Shah, et al., "BMS-354825: a Novel Drug with Potential for the Treatment of Imatinib-Resistant Chronic Myeloid Leukaemia", Expert Opin. Investig. Drugs, Vol. 14(1), pp. 89-91 (2005)	
	3AC	Staunton, et al., "Chemosensitivity Prediction by Transcriptional Profiling", PNAS, Vol. 98, pp. 10787-10792 (2001)	
	3AD	Susa, et al., "Src Inhibitors: Drugs for the Treatment of Osteoporosis, Cancer or Both", TIPS, Vol. 21, pp. 489-495 (2000)	
	3AE	Talpaz, et al., "Dasatinib in Imatinib-Resistant Philadelphia Chromosome-Positive Leukemias", N. Engl. J. Med., Vol. 354, pp. 2531-2541 (2006)	
	3AF	Thomas, et al., "Cellular Functions Regulated by SRC Family Kinases", Annu. Rev. Cell Dev. Biol., Vol. 13, pp. 513-609 (1997)	
	3AG	Van de Rijn, et al., "Expression of Cytokeratins 17 and 5 Identifies a Group of Breast Carcinomas with Poor Clinical Outcome", Am. J. Path., Vol. 161(6), pp. 1991-1996 (2002)	
	3AH	Vekris, et al., "Molecular Determinants of the Cytotoxicity of Platinum Compounds: The Contribution of <i>in Silico</i> Research", Can. Res., Vol. 64, pp. 356-362 (2004)	
	3AI	Verbeek, et al., "c-Src Protein Expression is Increased in Human Breast Cancer. An Immunohistochemical and Biochemical Analysis", J. Path., Vol. 180, pp. 383-388 (1996)	
	3AJ	Warmuth, et al., "Src Family Kinases: Potential Targets for the Treatment of Human Cancer and Leukemia", Curr. Pharm. Design, Vol. 9, pp. 2043-2059 (2003)	
	3AK	Weis, et al., "Endothelial Barrier Disruption by VEGF-Mediated Src Activity Potentiates Tumor Cell Extravasation and Metastasis", J. Cell Biol., Vol. 167(2), pp. 223-229 (2004)	
	3AL	Yamanashi, et al., "The yes-Related Cellular Gene <i>lyn</i> Encodes a Possible Tyrosine Kinase Similar to p56 <sup>lck</sup> ", Molec. Cell. Biol., Vol. 7(1), pp. 237-243 (1987)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant

Case No.: D0273 NP

Application No.: 10/648,593

Mailing Date: 10/5/06

Express Mail No.: \_\_\_\_\_

The Patent & Trademark Office acknowledges, and has stamped  
hereon the date of receipt of the items checked below:

☐ Transmittal Letter

☐ Provisional

☐ Non-provisional

☐ CIP ☐ DIV ☐ CONT

☐ RCE

☐ Specification \_\_\_\_\_ pages

☐ Drawings \_\_\_\_\_ pages

☐ Sequence Listing \_\_\_\_\_ pages/disk

☐ Statement of Verification

☐ Preliminary Amendment

☐ Executed/Unexecuted Declaration

☐ Response to Missing Parts

☐ Assignment Recordation Request

☐ Response to Restriction Requirement

☒ IDS

☒ 1449 Form 3 pages

☒ No. Of References 38

☐ Amendment/Response/Letter

☐ Amendment After Final

☐ Petition For Extension of Time

☐ Notice of Appeal

☐ Appeal Brief

☐ Issue Fee Payment

☒ Other FEC 14R

FM060019-1

SCP